CTCX vs. TLSI, DCTH, NPCE, PROF, DRTS, ARAY, CLPT, CVRX, TELA, and QIPT
Should you be buying Carmell stock or one of its competitors? The main competitors of Carmell include TriSalus Life Sciences (TLSI), Delcath Systems (DCTH), NeuroPace (NPCE), Profound Medical (PROF), Alpha Tau Medical (DRTS), Accuray (ARAY), ClearPoint Neuro (CLPT), CVRx (CVRX), TELA Bio (TELA), and Quipt Home Medical (QIPT). These companies are all part of the "surgical & medical instruments" industry.
Carmell (NASDAQ:CTCX) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, community ranking, dividends and earnings.
TriSalus Life Sciences has a consensus target price of $13.33, indicating a potential upside of 86.22%. Given TriSalus Life Sciences' higher probable upside, analysts clearly believe TriSalus Life Sciences is more favorable than Carmell.
In the previous week, TriSalus Life Sciences had 2 more articles in the media than Carmell. MarketBeat recorded 6 mentions for TriSalus Life Sciences and 4 mentions for Carmell. Carmell's average media sentiment score of 0.72 beat TriSalus Life Sciences' score of 0.64 indicating that Carmell is being referred to more favorably in the media.
TriSalus Life Sciences' return on equity of 0.00% beat Carmell's return on equity.
24.2% of Carmell shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 76.2% of TriSalus Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
TriSalus Life Sciences received 3 more outperform votes than Carmell when rated by MarketBeat users.
Carmell has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500.
Carmell has higher earnings, but lower revenue than TriSalus Life Sciences.
Summary
TriSalus Life Sciences beats Carmell on 8 of the 12 factors compared between the two stocks.
Get Carmell News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTCX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
